LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

Home・Akcijų sąrašas・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

21.35 0.19

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

21.28

Max

21.35

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-1.6M -21M
Pardavimai	14M 54M
Pelno marža	-39.611
Darbuotojai	178
EBITDA	-3.8M -23M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	-2.11% downside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	1B 2.2B
Ankstesnė atidarymo kaina	21.16
Ankstesnė uždarymo kaina	21.35

Naujienos nuotaikos

By Acuity

50%

150 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

6.26 / 7.47 Palaikymas ir pasipriešinimas

Day One Biopharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-16 21:37; UTC

Įsigijimai, susijungimai, perėmimai

Lensar and Alcon Agree to Terminate Merger

2026-03-16 19:06; UTC

Svarbiausios naujienos

Mideast Loses 12 Million Boe/d Following Hormuz Closure: Rystad -- OPIS

2026-03-16 17:44; UTC

Įsigijimai, susijungimai, perėmimai

Novartis Issues Debt Offering to Help Fund $12 Billion Acquisition of Avidity Biosciences

2026-03-16 23:46; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-16 23:46; UTC

Rinkos pokalbiai

Nikkei May Rise After Oil Prices Decline -- Market Talk

2026-03-16 23:37; UTC

Rinkos pokalbiai

Gold Edges Higher on Possible Technical Recovery -- Market Talk

2026-03-16 23:05; UTC

Rinkos pokalbiai

Slumping Consumer Confidence Highlights Risk Around RBA Hike -- Market Talk

2026-03-16 21:56; UTC

Rinkos pokalbiai

DUG Technology's Stock Fall Creates Opportunity -- Market Talk

2026-03-16 21:41; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Global Equities Roundup: Market Talk

2026-03-16 21:41; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Clouds Gather Over Auckland Intl Airport as Airlines Up Fares -- Market Talk

2026-03-16 20:59; UTC

Įsigijimai, susijungimai, perėmimai

Alcon: Transaction Unattractive to Pursue Further in Light of FTC's Opposition

2026-03-16 20:59; UTC

Įsigijimai, susijungimai, perėmimai

Alcon: Delay and Associated Costs of Extended Regulatory Review Has Rendered Deal Unattractive to Pursue Further

2026-03-16 20:59; UTC

Įsigijimai, susijungimai, perėmimai

Alcon Entered Agreement With LENSAR to Terminate Merger Agreement

2026-03-16 20:57; UTC

Įsigijimai, susijungimai, perėmimai

Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement

2026-03-16 20:51; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia-Backed Nscale Plans Huge Data Center Cluster in West Virginia -- WSJ

2026-03-16 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-03-16 20:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Energy & Utilities Roundup: Market Talk

2026-03-16 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-03-16 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-03-16 19:53; UTC

Svarbiausios naujienos

U.S. Allies Rebuff Trump's Demand for Help Opening Strait of Hormuz -- WSJ

2026-03-16 19:43; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-03-16 19:43; UTC

Rinkos pokalbiai

Nvidia Sees $1 Trillion in Blackwell, Rubin Orders Through 2027 -- Market Talk

2026-03-16 19:37; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Natural Gas Follows Oil Prices Lower -- Market Talk

2026-03-16 19:20; UTC

Svarbiausios naujienos

Stock Market Today: Dow Jumps, Brent Crude Pulls Back From $105 -- WSJ

2026-03-16 19:17; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Crude Oil Sinks on Signals from Strait of Hormuz -- Market Talk

2026-03-16 19:00; UTC

Rinkos pokalbiai

Bank of Canada Needs Dovish Approach Based on Weak Data -- Market Talk

2026-03-16 18:23; UTC

Rinkos pokalbiai

LME Restarts Trading After Outage -- Market Talk

2026-03-16 17:36; UTC

Svarbiausios naujienos

Oil Prices Fall as Trump Says Hormuz Help Is Coming. Tankers Getting Through, Bessent Adds. -- Barrons.com

2026-03-16 17:19; UTC

Rinkos pokalbiai

Grains Sink as Investors Steer Toward Equities -- Market Talk

2026-03-16 17:14; UTC

Svarbiausios naujienos

Trump Ends News Conference

Akcijų palyginimas

Kainos pokytis

Day One Biopharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

-2.11% į apačią

12 mėnesių prognozė

Vidutinis 20.86 USD -2.11%

Aukščiausias 21.5 USD

Žemiausias 17 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Day One Biopharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių Day One Biopharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

6.26 / 7.47Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Rinkos nuotaikos

By Acuity

150 / 351 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.